TEVA

EX-99.1

2 exh_991.htm

PRESS RELEASE

EdgarFiling

EXHIBIT 99.1

Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501

Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules (a generic version of Revlimid®) in the U.S. This decrease was partially offset by continued strong growth across Teva’s key innovative brands.

Strong profitability: Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025; non-GAAP gross profit margin increased to the highest quarterly level in the last decade, by 345 basis points to 58.7%, excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025; operating income was $714 million and non-GAAP operating income was $1,393 million; diluted earnings per share (EPS) was $0.20 and non-GAAP diluted EPS was $0.86; cash flow generated from operating activities was $241 million and free cash flow was approximately $0.5 billion.

Key innovative brands continued to drive Teva’s portfolio transformation, collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency:

AUSTEDO global revenues were $751 million, increasing 21% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $2.55 billion–$2.65 billion, from $2.45 billion–$2.60 billion.

AJOVY global revenues were $269 million, increasing 61% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $930 million–$960 million, from $850 million–$870 million.

UZEDY revenues were $85 million, increasing 96% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $290 million–$310 million, from $270 million–$290 million.

Building the next wave of neuroscience growth: Teva received FDA approval for WELTRUZA in the U.S. in October 2026, marking a significant expansion for long-acting injectable schizophrenia treatment and highlighting Teva’s established commercial capabilities and deep understanding of the patient journey. The Company continues to target LAI schizophrenia portfolio (UZEDY and WELTRUZA) with peak sales potential of $1.5 billion–$2.0 billion.

Expanding Teva’s growth through strategic business development:

Acquired BXCL-501, from BioXcel Therapeutics Inc., which is under FDA review for potential at-home use for the acute treatment agitation associated with schizophrenia or bipolar I or II disorder in adults;

Deepened collaboration with Samsung Bioepis for the commercialization of two additional biosimilars, infliximab-abda, a biosimilar to Remicade® (infliximab), and etanercept-ykro, a biosimilar to Enbrel® (etanercept), expanding the Company’s burgeoning global pipeline and portfolio of biosimilars.

Generics and biosimilars remain an important foundation: global generics revenues decreased 16% year-over-year in local currency, primarily reflecting lower U.S. revenues from lenalidomide capsules (a generic version of Revlimid®), partially offset by recently launched generic products and growth in biosimilars. Teva’s biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.

Innovative pipeline successes strengthen Teva’s longer-term growth profile with the potential to launch at least one product per year over five years:

The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.

Teva reported positive Phase 2a results for anti-IL-15 (TEV-‘408) in Celiac disease, and is targeting to begin Phase 2b in vitiligo in Q4 2026.

Teva discontinued its phase 2 Multiple System Atrophy (MSA) study of emrusolmin (TEV-‘286), following an interim futility analysis that indicated low probability of the study meeting its primary efficacy endpoint if continued.

Financial strength, with continued value creation for shareholders: the return to an investment grade credit rating, refinancing of ~$4.9 billion in debt during Q3 2026, and the direct listing of Teva's ordinary shares on the New York Stock Exchange (NYSE); all reflect Teva's strong execution of its Pivot to Growth strategy, continued financial strength and long-term shareholder value creation.

Finalized Most-Favored-Nation (MFN) agreement with the U.S. Administration, including a prospective pricing

commitment with respect to certain future innovative product launches.

Q3 2026 Highlights:

Revenues